Abstract:
Current scientific data regarding the role of metabolic abnormalities in the development and progression of metabolically associated fatty liver disease, as well as the assessment
of existing approaches to their management, have been analyzed. It is demonstrated that dyslipidemia, insulin resistance,
and obesity are not only key risk factors for the development
of metabolically associated fatty liver disease but also contribute to increased cardiovascular morbidity and mortality
in this patient population. Current non-pharmacological and
pharmacological therapeutic strategies aimed at correcting
metabolic abnormalities and reducing the risk of disease progression are reviewed.
